Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Open Access
- 31 January 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (1), e16172
- https://doi.org/10.1371/journal.pone.0016172
Abstract
Huntington's disease (HD) is an autosomal dominantly inherited progressive neurodegenerative disease. The exact sequel of events finally resulting in neurodegeneration is only partially understood and there is no established protective treatment so far. Some lines of evidence speak for the contribution of oxidative stress to neuronal tissue damage. The fumaric acid ester dimethylfumarate (DMF) is a new disease modifying therapy currently in phase III studies for relapsing-remitting multiple sclerosis. DMF potentially exerts neuroprotective effects via induction of the transcription factor “nuclear factor E2-related factor 2” (Nrf2) and detoxification pathways. Thus, we investigated here the therapeutic efficacy of DMF in R6/2 and YAC128 HD transgenic mice which mimic many aspects of HD and are characterized by an enhanced generation of free radicals in neurons. Treatment with DMF significantly prevented weight loss in R6/2 mice between postnatal days 80–90. At the same time, DMF treatment led to an attenuated motor impairment as measured by the clasping score. Average survival in the DMF group was 100.5 days vs. 94.0 days in the placebo group. In the histological analysis on day 80, DMF treatment resulted in a significant preservation of morphologically intact neurons in the striatum as well as in the motor cortex. DMF treatment resulted in an increased Nrf2 immunoreactivity in neuronal subpopulations, but not in astrocytes. These beneficial effects were corroborated in YAC128 mice which, after one year of DMF treatment, also displayed reduced dyskinesia as well as a preservation of neurons. In conclusion, DMF may exert beneficial effects in mouse models of HD. Given its excellent side effect profile, further studies with DMF as new therapeutic approach in HD and other neurodegenerative diseases are warranted.Keywords
This publication has 69 references indexed in Scilit:
- The Nrf2 System as a Potential Target for the Development of Indirect AntioxidantsMolecules, 2010
- Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and NeurodegenerationPLoS Biology, 2010
- Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the MousePLOS ONE, 2010
- Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseFree Radical Biology & Medicine, 2010
- Neurodegenerative diseases: exercising towards neurogenesis and neuroregenerationFrontiers in Aging Neuroscience, 2010
- Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse modelsNeurobiology of Disease, 2009
- Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyteProceedings of the National Academy of Sciences, 2009
- Nrf2 Activation in Astrocytes Protects against Neurodegeneration in Mouse Models of Familial Amyotrophic Lateral SclerosisJournal of Neuroscience, 2008
- Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's diseaseNeurobiology of Disease, 2008
- Dimethylfumarate Is an Inhibitor of Cytokine-Induced E-Selectin, VCAM-1, and ICAM-1 Expression in Human Endothelial CellsBiochemical and Biophysical Research Communications, 1997